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Abstract
Objective To examine the association between calcium intake and risk
of primary hyperparathyroidism in women.
Design Prospective cohort study.
Setting Nurses’ Health Study I, which originally recruited participants
from the 11 most populous states in the United States.
Participants 58 354 female registered nurses enrolled in the Nurses’
Health Study I aged 39-66 years in 1986 and with no history of primary
hyperparathyroidism. Calcium intake was assessed every four years
using semiquantitative questionnaires on food frequency.
Main outcome measure Incident primary hyperparathyroidism,
confirmed by medical record review.
Results During 22 years of follow-up, we recorded 277 incident cases
of primary hyperparathyroidism. Women were divided into five equal
groups, according to intake of dietary calcium. After adjusting for age,
body mass index, race, and other factors, the relative risk of primary
hyperparathyroidism for women in the group with the highest intake of
dietary calcium was 0.56 (95% confidence interval 0.37 to 0.86, P=0.009
for trend), compared with the group with the lowest intake. The
multivariable relative risk of primary hyperparathyroidism for women
taking more than 500 mg/day of calcium supplements compared with
no calcium supplements was 0.41 (95% confidence interval 0.29 to 0.60,
P<0.001 for trend). Analyses restricted to participants with regular
physical exams did not significantly change the association between
calcium intake and risk of primary hyperparathyroidism.
Conclusion Increased calcium intake is independently associated with
a reduced risk of primary hyperparathyroidism in women.
Introduction
Primary hyperparathyroidism is the most common cause of
hypercalcemia
1andthethirdmostcommonendocrinedisorder,
with 100 000 new cases in the United States each year.
2 Up to
2% of postmenopausal women could have this condition.
3 4
Primaryhyperparathyroidismischaracterizedbyhypercalcemia
with a high or insufficiently suppressed level of parathyroid
hormone, and is caused by a solitary parathyroid adenoma in
85-90%ofpatients.
5 6Associatedmorbiditiesandcostlysequelae




9 Monogenic disorders (such as multiple
endocrine neoplasia I and II)
10 account for fewer than 5% of
cases,
11 and neck irradiation also accounts for only a small
fraction of cases.
12
Because the parathyroid adenoma of sporadic primary
hyperparathyroidismismonoclonal,
13-15factorsthatchronically
stimulate parathyroid hormone and increase the probability of
aparathyroidcellundergoingasomaticmutationandsubsequent




17-22 and therefore could be important
in the pathogenesis of primary hyperparathyroidism. However,
nostudytodatehasprospectivelyexploredtherelationbetween
calcium intake and risk of developing primary
hyperparathyroidism.
Toexaminetheassociationbetweencalciumintakeandtherisk
of incident primary hyperparathyroidism, we conducted a
prospectivestudyof58354womenintheNurses’HealthStudy
I without history of primary hyperparathyroidism at baseline.
Methods
Study population
The Nurses’ Health Study I is an ongoing, prospective cohort
studywhichbeganin1976,enrolling121700femaleregistered
nurses between 30 and 55 years of age and residing in 11 US
states. The cohort is followed by using questionnaires mailed
every two years that ask about lifestyle practices and newly
diagnosed diseases. The average proportion of participants
followed up has been more than 90%. The sample for our
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Research
RESEARCHanalysis was limited to the 58 354 women who answered either
the 2006 or 2008 questionnaires, which included questions on
lifetime history of primary hyperparathyroidism. The study
protocol was reviewed and approved by the Brigham and
Women’s Hospital institutional review board.
Assessment of dietary intake
To assess the participants’ diet, we used semiquantitative




1998, 2002, and 2006. Intake of specific dietary factors was
computed from the reported frequency of consumption of each
specified unit of food and from US Department of Agriculture
dataonthecontentoftherelevantnutrientinspecifiedportions.
Nutrient values were adjusted for total energy intake to
determine the nutrient composition of the diet independent of
thetotalamountoffoodeaten.Thefoodfrequencyquestionnaire
also asked about the use of calcium supplements, vitamin D
supplements, and multivitamins. The intake of supplemental
calcium, vitamin A, and vitamin D in multivitamins or in
isolatedformweredeterminedbythebrand,type,andfrequency
of reported use.
The food frequency questionnaire has been extensively
validated.
23Inasampleof173participantsintheNurses’Health
Study I, nutrient intake reported on two food frequency
questionnaires was compared with four seven-day records kept
by the nurses who weighed and measured everything they ate
or drank.
24 The values for the nutrient data on the two food
frequency questionnaires and the food diaries were highly
correlated, and the degree of reproducibility was not modified
by obesity or other personal characteristics. For example,
correlation coefficients were 0.81 for skim or low fat milk and
0.94 for yogurt.
24
Assessment of non-dietary factors
Age, body mass index, smoking status (never, past, current),
physical activity (in metabolic equivalent task scores), history
of diabetes, hypertension, diuretic use, menopausal status, and
postmenopausalhormoneusewereascertainedfromthebiennial
questionnaires.Selfreportedweightwashighlyreliable(r=0.97)
among a subset of participants who underwent direct
measurementoftheirweight.
25Physicalactivityreportedonthe
questionnaires has been previously validated against physical
activity diaries (r=0.79).




age at menopause and type of menopause were previously
validated in the Nurses’ Health Study I and shown to be highly
accurate.
29 Race was self reported and categorized in this
analysis as white and non-white.
Assessment of cases
Participants were asked about a diagnosis of
hyperparathyroidism on the 2006 and 2008 questionnaires. On
the 2008 questionnaire, nurses were also asked about lifetime
history of hyperparathyroidism. To identify primary (v
secondary)hyperparathyroidism,wesubsequentlyobtainedthe
medical records of all participants who gave consent. We
confirmed cases of primary hyperparathyroidism by pathology
report of a resected adenoma or by elevated serum
concentrations of calcium (≥10.6 mg/dL; 1 mg/dL=0.25
mmol/L) with high or insufficiently suppressed parathyroid
hormone
30-34(≥50pg/mL;1pg/mL=1ng/L).Themedicalrecord
confirmation rate was 75%. Cases were rejected after medical
record review for a variety of reasons, most commonly
incomplete data or identification of secondary
hyperparathyroidism from vitamin D deficiency or renal
insufficiency.
We included in the analysis only cases of primary
hyperparathyroidism that were diagnosed during the 22 years
betweenthedateonwhichthe1986questionnairewasreturned
and 31 May 2008. Participants with a history of primary
hyperparathyroidism at baseline were excluded from the study.
Statistical analyses
The study design was prospective; information on diet was
collectedbeforethediagnosisofprimaryhyperparathyroidism.
For each participant, we counted person months of follow-up
from the date on which the 1986 questionnaire was returned to
the date on which primary hyperparathyroidism was diagnosed
or death occurred, or 31 May 2008, whichever occurred first.
Information on exposures of interest that was recorded in
response to the 1986 questionnaire was updated on subsequent
questionnaires.Weallocatedpersontimeoffollow-upaccording
toexposurestatusatthestartofeachfollow-upperiod.Dividing
the cohort into five equal groups of nutrient intake allowed us
to examine a wide range of nutrient intake while maintaining
enough participants in the highest and lowest categories. If
complete information on diet was missing at the start of a time
period, the participant was excluded from that time period.
The relative risk—the incidence among women in a particular
category of intake divided by the corresponding rate in the
comparison category—was used as the measure of association.
We used the Mantel extension test to evaluate linear trends
across categories of calcium intake. We used a proportional
hazards model to simultaneously adjust for several risk factors.
The variables considered in these models were age; body mass
index (<22, 22-24.9, 25-29.9, and ≥30); race (white or
non-white); physical activity level (divided into five equal
groupsofdifferinglevels);alcoholintake(none,0.1-4.9,5-14.9,
≥15 g/day); use of thiazide or loop diuretics (yes or no);
supplemental calcium intake (none, 1-500, >500 mg/day);
supplemental vitamin D intake (none, 1-400, >400 IU/day);
dietary intakes of calcium, vitamin D, vitamin A, and protein
(total and animal protein intake); self reported diabetes; self
reported hypertension; menopausal status; postmenopausal
hormone use; and physical exam during the prior two years.
Owing to the high correlation between the dietary intakes of
calcium and phosphorus (r≥0.68 for all follow-up periods), we
excluded phosphorus from the multivariable models. We
calculated 95% confidence intervals for all relative risks. All P
values were two tailed.
Results
Dietary calcium intake
During 1 475 978 person years of follow-up over a 22 year
period, we confirmed 277 cases of incident primary
hyperparathyroidism. Table 1⇓ shows the characteristics of the
cohort, divided into five equal groups according to energy
adjusted intake of dietary calcium in 1986. For our analyses,
however, the updated dietary values were used for each time
period. The mean daily intake of vitamin D, magnesium, total
protein,animalprotein,andvitaminA,andthephysicalactivity
level increased with increasing dietary calcium intake. The
average daily alcohol intake and the percentage of current
smokers decreased with increasing calcium intake. The
percentageofnurseswithselfreporteddiabetesorhypertension
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RESEARCHor who were taking thiazide diuretics and the mean daily intake
of supplemental calcium was similar across the five groups.
After adjusting for age, a higher intake of dietary calcium was
associated with a reduced risk of primary hyperparathyroidism
(table 2⇓). The relative risk for women in the group with the
highest intake of dietary calcium compared with women with
the lowest intake was 0.61 (95% confidence interval 0.42 to
0.90, P=0.03 for trend).
After further adjusting for body mass index, race, smoking
status, calcium supplement use, intake of vitamin D, dietary
intake of vitamin A and protein, alcohol intake, and diuretic
use, the adjusted relative risk for women in the group with the
highest intake of dietary calcium compared with women with
the lowest intake was 0.56 (95% confidence interval 0.37 to
0.86, P=0.009 for trend). The association between dietary
calcium and risk of primary hyperparathyroidism was similar
for calcium intakes not adjusted for energy.
Total calcium intake
After adjusting for age, higher total daily intake of calcium
(including dietary and supplemental calcium) was associated
with a reduced risk of primary hyperparathyroidism (table 2).
Forwomeninthegroupwiththehighestintakeoftotalcalcium
compared with women in the group with the lowest intake, the
relative risk was 0.48 (95% confidence interval 0.33 to 0.69,
P<0.001 for trend), and the multivariable relative risk was 0.41
(0.27 to 0.63, P<0.001 for trend).
Supplemental calcium intake
We also studied the relation between supplemental calcium
intake and risk of primary hyperparathyroidism. Because of an
insufficient number of cases of primary hyperparathyroidism
among the different categories of supplemental calcium use in
the earlier time periods, our analysis on the relation between
supplemental calcium intake and primary hyperparathyroidism
beganin1994withfollow-upuntil2008.During985628person
years of follow-up over a 14 year period, we documented 257
cases of incident primary hyperparathyroidism.
Higher supplemental calcium intake was associated with a
reduced risk of primary hyperparathyroidism (table 3⇓). After
adjusting for age, the relative risk for women taking more than
500 mg/day of calcium supplements compared with those not
takingcalciumsupplementswas0.69(95%confidenceinterval
0.50 to 0.94, P<0.001 for trend). The multivariable relative risk
for the same comparison, including adjustment for dietary





we performed analyses with additional adjustment for having
a physical exam (yes or no) during the prior two years of each
time period in our multivariable analysis. The association
between increased calcium intake and lower risk of primary
hyperparathyroidism was similar after adjusting for regular
physicalexams,andwassimilarinanalysesrestrictedtowomen
who had a physical exam during the prior two years of each
time period.
Since the incidence of primary hyperparathyroidism seems to
increase with age,
36 37 we also performed stratified analysis by
age (≥65 and <65 years). The association between increased
calciumintakeandreducedriskofprimaryhyperparathyroidism
was similar in older and younger women (P=0.21 for
interaction); it was also similar after adjusting for menopausal
status and use of postmenopausal hormone use. Since calcium
absorption can depend on vitamin D status, we also performed
analyses stratified by median total intake of vitamin D. The
associations between higher calcium intake and decreased risk
ofprimaryhyperparathyroidismweresimilaramongparticipants
above and below this median level.
We also examined the association between cumulative calcium
intake and risk of primary hyperparathyroidism, and the results
were similar. Because we could not exclude the possibility that
physicians stopped calcium supplements in participants with
higher serum calcium concentrations shortly before primary
hyperparathyroidism diagnosis, we also performed analyses
with a four year lag between assessment of supplemental
calciumuseandprimaryhyperparathyroidism.Inmultivariable
lag analyses, the relative risk of primary hyperparathyroidism
was 0.79 (95% confidence interval 0.57 to 1.09) for women





To our knowledge, we report results from the first prospective
studyoftherelationbetweencalciumintakeandriskofprimary
hyperparathyroidism. In women, increased dietary and
supplementalcalciumintakewasassociatedwithareducedrisk
for developing primary hyperparathyroidism, independent of
age, body size, diet, and other factors.
Comparison with other studies
Several studies have examined the effect of calcium intake in
patients already diagnosed with primary hyperparathyroidism,
with differing results.
38-41 Insogna and colleagues
39 found that
calcium intake of 1000 mg/day compared with 400 mg/day
suppressed the mean fasting level of parathyroid hormone by
19% among 18 study participants with primary
hyperparathyroidism.Jordeandcolleagues
40foundthatthelevel
of parathyroid hormone decreased after four weeks in 17 of 24
participantswithprimaryhyperparathyroidismwhoweregiven
calcium supplementation. On the other hand, Locker and
colleagues
41foundnosignificanteffectofdietarycalciumintake
on serum parathyroid hormone level among 71 participants
alreadydiagnosedwithprimaryhyperparathyroidism.However,
no study has prospectively examined the association between
calcium intake and risk of developing primary
hyperparathyroidism.
Limitations of the study
There are several limitations to our study. Firstly, since our
study population was female and almost entirely white, our
findingsarenotnecessarilygeneralizabletomenorotherraces.
Secondly, we cannot exclude selection bias. We only included
cases confirmed by medical record review, and we could not
obtainmedicalrecordsforallwomenwhoselfreportedprimary
hyperparathyroidism. Thirdly, although the food frequency
questionnaires have been well validated, calcium intake was
not perfectly assessed in this study. However, because of the
prospectivedesign,anymisclassificationwouldberandomwith
respect to case status, and therefore would probably
underestimatethemagnitudeoftheinverseassociationbetween
calcium intake and risk of primary hyperparathyroidism.
Fourthly, many cases of primary hyperparathyroidism may be
asymptomatic and detected by routine blood work. However,
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RESEARCHin subanalyses restricted to women who had regular physical
exams, the inverse relation between calcium intake and risk of
developing primary hyperparathyroidism remained robust.
Fifthly, since we conducted an observational study, there could
be unknown confounders that we did not control for in our
analysis. Finally, the magnitude of the association between
higher supplemental calcium intake and lower risk of primary
hyperparathyroidism was attenuated in lag analyses. Thus, we
cannot exclude the possibility that some women with higher
valuesofserumcalciumonroutinebloodworkweretoldtostop
taking calcium supplements before their diagnosis of primary
hyperparathyroidism.
Areas for future research
Calciumintakecouldhavearoleinthepathogenesisofprimary
hyperparathyroidism by influencing the production of
parathyroid hormone.
17-22 The monoclonal nature of the single
parathyroid adenoma that causes the large majority of cases of
primary hyperparathyroidism
13-15 suggests a neoplasm that
originates from single cells with a growth-conferring mutation.
Because factors that cause parathyroid hyperplasia, such as
lowercalciumintake,increasetheprobabilitythataparathyroid
cell will undergo a somatic mutation and subsequent clonal
proliferation,suchfactorscouldincreasetheriskfordeveloping
primary hyperparathyroidism.
11 14 16 The peak disease incidence
occurring later in life also suggests that risk factors for primary
hyperparathyroidism could be due to a chronic stimulus over
time.
42Futureresearchshouldexamineotherenvironmentaland
lifestyle risk factors that could chronically stimulate the
parathyroid gland and thereby affect subsequent development
of primary hyperparathyroidism.
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Calcium intake is known to influence parathyroid hormone levels and therefore could be important in the pathogenesis of primary
hyperparathyroidism
No study to date has prospectively explored the relation between calcium intake and risk of developing primary hyperparathyroidism
What this study adds
Increased calcium intake, including both dietary and supplemental calcium, is independently associated with a reduced risk of developing
primary hyperparathyroidism in women
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Table 1| Age standardized baseline characteristics of women according to energy adjusted intake of dietary calcium in 1986
Dietary calcium intake
Group 5 (n=11 498) Group 4 (n=11 740) Group 3 (n=11 818) Group 2 (n=11 808) Group 1 (n=11 490)
52.4 51.8 51.7 51.4 51.3 Age (years)*
25.2 25.3 25.2 25.1 25.0 Body mass index
16.1 15.4 14.6 13.9 11.9 Physical activity (MET/week)
1115 811 672 564 431 Dietary calcium intake (mg/day)†
335 357 360 351 352 Calcium supplement intake (mg/day)
55 (6370) 58 (6775) 58 (6833) 56 (6654) 55 (6351) Calcium supplement use (% (No))
465 366 322 287 254 Total (dietary and supplemental) vitamin
D intake (IU/day)†
334 314 300 285 265 Magnesium intake (mg/day)†
81.3 76.8 74.4 72.5 70.1 Total protein intake (gm/day)†
62.1 56.2 53.5 51.7 50.3 Animal protein intake (gm/day)†
2493 2329 2205 2051 1842 Total (dietary and supplemental) vitamin
A intake (mcg/day)†
4.0 5.0 5.8 6.7 8.8 Alcohol intake (gm/day)
Smoking status (% (No))
50 (5760) 47 (5470) 46 (5458) 46 (5374) 43 (4955) Never smoker
35 (4052) 37 (4375) 37 (4358) 34 (4068) 33 (3776) Past smoker
15 (1686) 16 (1895) 17 (2002) 20 (2366) 24 (2758) Current smoker
3 (352) 3 (349) 2 (281) 2 (258) 2 (247) Self reported diabetes (% (No))
22 (2584) 23 (2648) 22 (2615) 22 (2620) 24 (2722) Self reported hypertension (% (No))
12 (1374) 12 (1450) 12 (1459) 12 (1392) 13 (1517) Thiazide use (% (No))‡
2 (196) 1 (171) 2 (195) 2 (181) 1 (171) Loop diuretic use (% (No))§
Data are mean values, or the percentages (and numbers) of participants that are standardized to the age distribution of the study population. Study population
divided into five equal groups according to intake of dietary calcium. MET=metabolic equivalent task scores.
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RESEARCHTable 2| Age adjusted and multivariable relative risks for incident primary hyperparathyroidism according to dietary and total calcium
intake*
P for trend Group 5 Group 4 Group 3 Group 2 Group 1
Dietary calcium intake
— 1070 806 670 564 443 Median within group
(mg/day)
— 44 50 57 57 69 No of cases of primary
hyperparathyroidism
— 292 944 297 109 298 068 296 872 290 985 No of person years
0.03 0.61 (0.42 to 0.90) 0.70 (0.49 to 1.01) 0.80 (0.56 to 1.14) 0.81 (0.57 to 1.15) 1.0 Age adjusted relative risk
(95% CI)
0.009 0.56 (0.37 to 0.86) 0.66 (0.45 to 0.98) 0.78 (0.54 to 1.11) 0.79 (0.55 to 1.13) 1.0 Multivariable relative risk
(95% CI)†
Total calcium intake
— 1794 1276 999 737 522 Median within group
(mg/day)
— 45 42 43 61 86 No of cases of primary
hyperparathyroidism
— 295 321 298 933 297 322 294 850 289 554 No of person years
<0.001 0.48 (0.33 to 0.69) 0.45 (0.31 to 0.65) 0.48 (0.33 to 0.69) 0.69 (0.50 to 0.96) 1.0 Age adjusted relative risk
(95% CI)
<0.001 0.41 (0.27 to 0.63) 0.39 (0.25 to 0.58) 0.42 (0.28 to 0.62) 0.64 (0.46 to 0.91) 1.0 Multivariable relative risk
(95% CI)‡
Population divided into five equal groups according to intake of calcium.
*For illustrative purposes, medians within each group for intake of dietary and total calcium were derived from responses to the 1986 dietary questionnaire. However,
the period specific medians were used for the 1986-2008 analysis. Relative risks are for the risk of primary hyperparathyroidism compared with the group that had
the lowest intake of dietary or total calcium (that is, group 1).
†Multivariable model includes age, body mass index (categories: <22, 22-24.9, 25-29.9, ≥30), race, smoking status (past, current, or never), calcium supplement
intake, total vitamin D intake, dietary intakes of vitamin A and protein, alcohol intake, and diuretic use (thiazide or loop diuretic use).
‡Multivariable model includes age, body mass index (categories: <22, 22-24.9, 25-29.9, ≥30), race, smoking status (past, current, or never), total vitamin D intake,
dietary intakes of vitamin A and protein, alcohol intake (categories: none, 0.1-4.9, 5-14.9, ≥15 g/day), and diuretic use (thiazide or loop diuretic use).
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RESEARCHTable 3| Age adjusted and multivariable relative risks for incident primary hyperparathyroidism according to supplemental calcium intake
P for trend
Supplemental calcium intake (mg/day)
>500 1-500 None
— 86 86 85 No of cases of primary
hyperparathyroidism
— 397 587 293 762 294 279 No of person years*
<0.001 0.69 (0.50 to 0.94) 0.99 (0.73 to 1.34) 1.0 Age adjusted relative risk (95% CI)
<0.001 0.41 (0.29 to 0.60) 0.82 (0.59 to 1.15) 1.0 Multivariable relative risk (95% CI)†
*Follow-up started in 1994 because of insufficient number of cases of primary hyperparathyroidism in participants taking supplemental calcium from 1984-93.
†Multivariable model includes: age, body mass index (categories: <22, 22-24.9, 25-29.9, ≥30), race, smoking status (past, current, never), dietary calcium intake,
total vitamin D intake, dietary intakes of vitamin A and protein, alcohol intake (categories: none, 0.1-4.9, 5-14.9, ≥15 g/day), and diuretic use (thiazide or loop
diuretic use).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e6390 doi: 10.1136/bmj.e6390 (Published 18 October 2012) Page 8 of 8
RESEARCH